Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 3—March 2024
Research

Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan

Cheng-Yi Lee, Hung-Wei KuoComments to Author , Yu-Lun Liu, Jen-Hsiang Chuang, and Jih-Haw Chou
Author affiliation: Author affiliations: Taiwan Centers for Disease Control, Taipei, Taiwan (C.-Y. Lee, H.-W. Kuo, Y.-L. Liu, J.-H. Chuang); Ministry of Health and Welfare, Taipei (J.-H. Chou)

Main Article

Figure 3

Vaccine effectiveness against hospitalization among persons >65 years of age in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector-based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against moderate and severe illness defined by hospitalization for persons >65 years of age. Red dots indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.

Figure 3. Vaccine effectiveness against hospitalization among persons >65 years of age in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector-based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against moderate and severe illness defined by hospitalization for persons >65 years of age. Red dots indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.

Main Article

Page created: February 15, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external